CA2556436C - Process for preparing anti-a.beta. antibody - Google Patents

Process for preparing anti-a.beta. antibody Download PDF

Info

Publication number
CA2556436C
CA2556436C CA2556436A CA2556436A CA2556436C CA 2556436 C CA2556436 C CA 2556436C CA 2556436 A CA2556436 A CA 2556436A CA 2556436 A CA2556436 A CA 2556436A CA 2556436 C CA2556436 C CA 2556436C
Authority
CA
Canada
Prior art keywords
antibody
peptide
cells
gel
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2556436A
Other languages
English (en)
French (fr)
Other versions
CA2556436A1 (en
Inventor
Ronald Bradley Demattos
Uma Kuchibhotla
Hsiu-Chiung Yang
Don B. Mcclure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2556436A1 publication Critical patent/CA2556436A1/en
Application granted granted Critical
Publication of CA2556436C publication Critical patent/CA2556436C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
CA2556436A 2004-02-23 2005-02-17 Process for preparing anti-a.beta. antibody Expired - Fee Related CA2556436C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
US60/546,764 2004-02-23
PCT/US2005/005198 WO2005082939A2 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (2)

Publication Number Publication Date
CA2556436A1 CA2556436A1 (en) 2005-09-09
CA2556436C true CA2556436C (en) 2014-04-01

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2556436A Expired - Fee Related CA2556436C (en) 2004-02-23 2005-02-17 Process for preparing anti-a.beta. antibody

Country Status (20)

Country Link
US (1) US20070190046A1 (https=)
EP (1) EP1720909B1 (https=)
JP (1) JP4851348B2 (https=)
KR (2) KR20090005410A (https=)
CN (1) CN1922209B (https=)
AT (1) ATE534667T1 (https=)
AU (1) AU2005217596B2 (https=)
BR (1) BRPI0507856A (https=)
CA (1) CA2556436C (https=)
CY (1) CY1112162T1 (https=)
DK (1) DK1720909T3 (https=)
EA (1) EA009872B1 (https=)
ES (1) ES2375627T3 (https=)
IL (1) IL177611A (https=)
NO (1) NO20064239L (https=)
PL (1) PL1720909T3 (https=)
PT (1) PT1720909E (https=)
SI (1) SI1720909T1 (https=)
UA (1) UA93181C2 (https=)
WO (1) WO2005082939A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
KR20120017469A (ko) 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
JP2010515717A (ja) 2007-01-11 2010-05-13 フィリップス−ウニベルジテート・マールブルク アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
JP5773879B2 (ja) 2008-11-25 2015-09-02 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 神経系の細胞の生存を促進するためのＤＲ６およびｐ７５のアンタゴニストの使用
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
KR20120103587A (ko) 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
PT3042917T (pt) * 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
HUE041391T2 (hu) 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
JP2019524788A (ja) * 2016-08-11 2019-09-05 イーライ リリー アンド カンパニー アミノチアジンおよびｂａｃｅ１阻害剤としてのそれらの使用
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002100B1 (ru) 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
BRPI0108676B8 (pt) * 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide

Also Published As

Publication number Publication date
CN1922209B (zh) 2012-09-05
DK1720909T3 (da) 2012-01-30
PL1720909T3 (pl) 2012-04-30
WO2005082939A2 (en) 2005-09-09
IL177611A (en) 2013-05-30
AU2005217596A1 (en) 2005-09-09
AU2005217596B2 (en) 2012-01-19
KR100889430B1 (ko) 2009-03-23
ES2375627T3 (es) 2012-03-02
SI1720909T1 (sl) 2012-01-31
CY1112162T1 (el) 2015-12-09
CN1922209A (zh) 2007-02-28
KR20060126785A (ko) 2006-12-08
BRPI0507856A (pt) 2007-07-10
KR20090005410A (ko) 2009-01-13
EP1720909A2 (en) 2006-11-15
EA009872B1 (ru) 2008-04-28
PT1720909E (pt) 2011-12-23
EA200601545A1 (ru) 2007-02-27
CA2556436A1 (en) 2005-09-09
JP2008500279A (ja) 2008-01-10
WO2005082939A3 (en) 2005-10-27
NO20064239L (no) 2006-11-20
UA93181C2 (ru) 2011-01-25
EP1720909B1 (en) 2011-11-23
US20070190046A1 (en) 2007-08-16
IL177611A0 (en) 2006-12-10
JP4851348B2 (ja) 2012-01-11
ATE534667T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
CA2556436C (en) Process for preparing anti-a.beta. antibody
US20240190952A1 (en) IL-18 Binding Protein (IL-18BP) and Antibodies for Treating Inflammatory Diseases
US11078261B2 (en) Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
TWI747922B (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
JP6462750B2 (ja) 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
CN109937210B (zh) 用于治疗共核蛋白病的药剂、用途和方法
KR101370253B1 (ko) 재조합 항체의 재접힘 방법
JP2003523764A (ja) Ａβペプチドを隔離するヒト化抗体
KR20090019911A (ko) 아밀로이드 β(1-42) 올리고머, 이의 유도체, 이에 대한 항체, 이의 제조 방법 및 용도
KR20080090408A (ko) 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
CN110072888B (zh) 药剂、用途和方法
MXPA06009560A (en) Anti-abeta antibody
US20250353904A1 (en) Preventative Agent or Therapeutic Agent for Amyotrophic Lateral Sclerosis, Parkinson&#39;s Disease, Huntington&#39;s Disease, Spinocerebellar Ataxia, Aging-Related Degenerative or Neurological Disease, Brain Aging, or Diseases Associated With Brain Aging
US20240025985A1 (en) Agent for Preventing or Treating Frontotemporal Lobar Degeneration
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170217